![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/5/5f/Berdazimer_sodium.svg/640px-Berdazimer_sodium.svg.png&w=640&q=50)
Berdazimer sodium
Medication / From Wikipedia, the free encyclopedia
Berdazimer sodium, sold under the brand name Zelsuvmi, is a medication used for the treatment for molluscum contagiosum.[1] Berdazimer sodium is a nitric oxide releasing agent.[1] It is a polymer formed from sodium 1-hydroxy-3-methyl-3-(3-(trimethoxysilyl)propyl)-1-triazene-2-oxide and tetraethyl silicate.[2]
Quick Facts Clinical data, Trade names ...
![]() | |
Clinical data | |
---|---|
Trade names | Zelsuvmi |
Other names | SB206 |
License data | |
Routes of administration | Topical |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | Indeterminate[1] |
Molar mass | Indeterminate[1] |
Close
Berdazimer sodium was approved for medical use in the United States in January 2024.[3][4][5]